Hikal

Hikal

HIKAL.NSPre-clinical
Mumbai, IndiaFounded 1988hikal.com

Hikal is a diversified chemical company with a strong focus on the pharmaceutical and agrochemical sectors, operating as a key partner for global innovators and generic companies. With decades of experience, it has built significant capabilities in research, process development, and manufacturing of high-value intermediates and APIs. The company's strategy is centered on expanding its CDMO services, investing in new technologies, and strengthening its position in regulated markets. Its financial stability is underpinned by a long-standing public listing and a diversified customer base.

Market Cap
$222.0M
Founded
1988
Employees
2000-3000
Focus
Biotech

HIKAL.NS · Stock Price

USD 168.62188.53 (-52.79%)

Historical price data

AI Company Overview

Hikal is a diversified chemical company with a strong focus on the pharmaceutical and agrochemical sectors, operating as a key partner for global innovators and generic companies. With decades of experience, it has built significant capabilities in research, process development, and manufacturing of high-value intermediates and APIs. The company's strategy is centered on expanding its CDMO services, investing in new technologies, and strengthening its position in regulated markets. Its financial stability is underpinned by a long-standing public listing and a diversified customer base.

Technology Platform

Expertise in complex chemical synthesis, process development, and scale-up manufacturing for pharmaceuticals and agrochemicals, serving as a Contract Development and Manufacturing Organization (CDMO).

Funding History

1
IPOUndisclosedUndisclosedJun 15, 1995

Opportunities

Growth is driven by the global pharmaceutical outsourcing trend, the 'China Plus One' supply chain strategy, and increasing demand for complex chemistry and High-Potency API (HPAPI) manufacturing.
Expansion of service offerings into more integrated drug development solutions presents a significant upside.

Risk Factors

Key risks include regulatory non-compliance at manufacturing sites, high client concentration, volatility in raw material costs and currency exchange rates, and intense competition in the CDMO sector putting pressure on pricing and margins.

Competitive Landscape

Hikal competes with large Indian CDMOs like Divi's Laboratories and Syngene International, as well as global players. Its differentiation lies in deep expertise in complex chemical synthesis, a diversified business across pharma and agrochemicals, and long-standing relationships with multinational clients.

Publications
9
Patents
7

Company Info

TypeServices
Founded1988
Employees2000-3000
LocationMumbai, India
StagePre-clinical
RevenueRevenue Generating

Trading

TickerHIKAL.NS
ExchangeNSE

Contact

hikal.com+91-22-6652 1000

Therapeutic Areas

OncologyCentral Nervous System (CNS)CardiologyAnti-infectives

Partners

Global Pharmaceutical CompaniesGlobal Agrochemical Companies
SIMILAR COMPANIES
Mankind Pharma
Mankind Pharma
Pre-clinical · New Delhi
Sun Pharmaceutical
Sun Pharmaceutical
Pre-clinical ·
Lupin Limited
Lupin Limited
Pre-clinical ·
Aurobindo Pharma
Aurobindo Pharma
Pre-clinical · Hyderabad
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories
Pre-clinical · Princeton
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile